Literature DB >> 21345109

Resistance to BRAF inhibition in melanomas.

David B Solit1, Neal Rosen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21345109     DOI： 10.1056/NEJMcibr1013704

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  114 in total

1.  BRAFV600E mutation and papillary thyroid cancer: chicken or egg?

Authors:  Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2012-07       Impact factor: 5.958

Review 2.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

3.  The importance of Raf dimerization in cell signaling.

Authors:  Alyson K Freeman; Daniel A Ritt; Deborah K Morrison
Journal:  Small GTPases       Date:  2013-08-28

Review 4.  Tumor adaptation and resistance to RAF inhibitors.

Authors:  Piro Lito; Neal Rosen; David B Solit
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.

Authors:  Patrick J Roberts; Jerry E Usary; David B Darr; Patrick M Dillon; Adam D Pfefferle; Martin C Whittle; James S Duncan; Soren M Johnson; Austin J Combest; Jian Jin; William C Zamboni; Gary L Johnson; Charles M Perou; Norman E Sharpless
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

Review 6.  [Treatment of advanced metastatic melanoma].

Authors:  S Ugurel; J C Becker
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

7.  Melanoma--the pieces of the puzzle finally start coming together! Preface.

Authors:  Alan Spatz; Alexander M M Eggermont
Journal:  Mol Oncol       Date:  2011-04-03       Impact factor: 6.603

8.  Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

Authors:  Spyros Retsas
Journal:  J R Soc Med       Date:  2011-06       Impact factor: 5.344

9.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

Review 10.  Vemurafenib: the first drug approved for BRAF-mutant cancer.

Authors:  Gideon Bollag; James Tsai; Jiazhong Zhang; Chao Zhang; Prabha Ibrahim; Keith Nolop; Peter Hirth
Journal:  Nat Rev Drug Discov       Date:  2012-10-12       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.